Should I buy or sell AC Immune stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACIU shares. View ACIU analyst ratings or view top-rated stocks .

What is AC Immune's stock price target for 2024?

1 Wall Street analysts have issued 12-month price targets for AC Immune's shares. Their ACIU share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price. View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts .

How have ACIU shares performed in 2023?

AC Immune's stock was trading at $2.04 at the beginning of 2023. Since then, ACIU stock has increased by 56.9% and is now trading at $3.20. View the best growth stocks for 2023 here .

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our ACIU earnings forecast .

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings data on Friday, November, 3rd. The company reported ($0.20) earnings per share for the quarter.

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com . Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE) , Agenus (AGEN) , Aldeyra Therapeutics (ALDX) , Dynavax Technologies (DVAX) , Abeona Therapeutics (ABEO) , AVEO Pharmaceuticals (AVEO) , Catalyst Pharmaceuticals (CPRX) , Ocular Therapeutix (OCUL) , Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV) .

When did AC Immune IPO?

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's stock is owned by a number of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (3.55%), Tower Research Capital LLC TRC (0.02%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

AC Immune Stock Price, News & Analysis (NASDAQ:ACIU)

$3.20

0.00 (0.00%)

(As of 01:40 PM ET)

Compare

Today's Range: $3.03
▼
$3.21
50-Day Range: $2.46
▼
$3.24
52-Week Range: $1.68
▼
$3.83

Volume: 28,047 shs
Average Volume: 346,323 shs
Market Capitalization: $267.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

AC Immune MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 400.0% Upside
$16.00 Price Target
Short Interest: Bearish
1.36% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.68) to ($0.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

801st out of 949 stocks

Pharmaceutical Preparations Industry

387th out of 437 stocks

3.5

Analyst's Opinion

Consensus Rating
AC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, AC Immune has a forecasted upside of 400.0% from its current price of $3.20.
Amount of Analyst Coverage
AC Immune has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
1.36% of the float of AC Immune has been sold short.
Short Interest Ratio / Days to Cover
AC Immune has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
Change versus previous month
Short interest in AC Immune has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
AC Immune does not currently pay a dividend.
Dividend Growth
AC Immune does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACIU.

2.7

News and Social Media Coverage

News Sentiment
AC Immune has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for AC Immune this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AC Immune insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of AC Immune is held by insiders.
Percentage Held by Institutions
Only 19.17% of the stock of AC Immune is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AC Immune are expected to grow in the coming year, from ($0.68) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AC Immune is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AC Immune is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AC Immune has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AC Immune Stock (NASDAQ:ACIU)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

ACIU Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACIU Stock News Headlines

November 20, 2023 | finance.yahoo.com

FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success

November 17, 2023 | morningstar.com

AC Immune SA ACIU

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 9, 2023 | finance.yahoo.com

Are Medical Stocks Lagging AC Immune (ACIU) This Year?

November 7, 2023 | finance.yahoo.com

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

November 3, 2023 | finance.yahoo.com

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

November 2, 2023 | finance.yahoo.com

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023

October 27, 2023 | finance.yahoo.com

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

October 24, 2023 | finance.yahoo.com

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

October 18, 2023 | finance.yahoo.com

NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?

October 17, 2023 | finance.yahoo.com

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

October 6, 2023 | finance.yahoo.com

Further weakness as AC Immune (NASDAQ:ACIU) drops 14% this week, taking five-year losses to 69%

October 5, 2023 | finance.yahoo.com

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

September 5, 2023 | finance.yahoo.com

Are Options Traders Betting on a Big Move in AC Immune (ACIU) Stock?

September 5, 2023 | finance.yahoo.com

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

September 5, 2023 | finance.yahoo.com

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

August 7, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on AC Immune SA (ACIU)

August 4, 2023 | finance.yahoo.com

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

August 4, 2023 | finance.yahoo.com

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

July 28, 2023 | finanznachrichten.de

AC Immune SA: AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

July 28, 2023 | finance.yahoo.com

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

July 26, 2023 | finance.yahoo.com

AC Immune SA Appoints New Chief Medical Officer

July 3, 2023 | finance.yahoo.com

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

July 2, 2023 | fool.com

Ac Immune (NASDAQ: ACIU)

June 30, 2023 | finance.yahoo.com

Why Shares of AC Immune Jumped This Week

June 28, 2023 | markets.businessinsider.com

AC Immune SA (ACIU) Gets a Buy from H.C. Wainwright

See More Headlines

Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACIU
CUSIP: N/A
CIK: 1651625
Web: www.acimmune.com
Phone: (121) 345-9121
Fax: 41-21-345-9120
Employees: 126
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.00
High Stock Price Target: $16.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +401.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,140,000.00
Net Margins: N/A
Pretax Margin: -7,417,700.00%
Return on Equity: -46.44%
Return on Assets: -41.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.36
Quick Ratio: 7.36

Sales & Book Value

Annual Sales: $4.12 million
Price / Sales: 64.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.70 per share
Price / Book: 1.88

Miscellaneous

Outstanding Shares: 83,620,000
Free Float: 79,773,000
Market Cap: $266.75 million
Optionable: Not Optionable
Beta: 0.72

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Andrea Pfeifer Ph.D. (Age 66)
Co-Founder, CEO & Director
Comp: $1.1M
Mr. Christopher Roberts (Age 34)
Interim CFO & VP of Finance
Mr. Piergiorgio Donati (Age 52)
Chief Technical Operations Officer
Dr. Marie Kosco-Vilbois (Age 65)
Chief Scientific Officer
Mr. Jean-Fabien Monin (Age 52)
Chief Administrative Officer
Mr. Howard Donovan (Age 48)
Chief HR Officer
Mr. Joshua Drumm Ph.D.
Head of Investor Relations
Mr. Alexandre Caratsch (Age 57)
General Counsel
Judith Moore
Global Head of Communications
Mr. Julian Snow
VP of U.S. Finance & Corporate Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ACIU Stock Analysis - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings or view top-rated stocks.
What is AC Immune's stock price target for 2024?: 1 Wall Street analysts have issued 12-month price targets for AC Immune's shares. Their ACIU share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts.
How have ACIU shares performed in 2023?: AC Immune's stock was trading at $2.04 at the beginning of 2023. Since then, ACIU stock has increased by 56.9% and is now trading at $3.20.
View the best growth stocks for 2023 here.
When is AC Immune's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ACIU earnings forecast.
How were AC Immune's earnings last quarter?: AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings data on Friday, November, 3rd. The company reported ($0.20) earnings per share for the quarter.
What is Andrea Pfeifer's approval rating as AC Immune's CEO?: 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV).
When did AC Immune IPO?: (ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.
Who are AC Immune's major shareholders?: AC Immune's stock is owned by a number of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (3.55%), Tower Research Capital LLC TRC (0.02%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of AC Immune?: Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACIU) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AC Immune Stock Price, News & Analysis (NASDAQ:ACIU)

AC Immune MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AC Immune Stock (NASDAQ:ACIU)

ACIU Stock Price History

ACIU Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ACIU Stock Analysis - Frequently Asked Questions

Overall MarketRank^™